Literature DB >> 30899382

Exploring potential biomarkers of early stage esophageal squamous cell carcinoma in pre- and post-operative serum metabolomic fingerprint spectrum using 1H-NMR method.

Zhongxian Yang1, Yanyan Liu1, Limin Ma2, Xuqing Wen2, Huanlin Ji3, Ke Li3.   

Abstract

Esophageal squamous cell carcinoma (ESCC) is one of the most prevalent types of upper gastrointestinal malignancy. Here, we used 1H nuclear magnetic resonance spectroscopy (1H-NMR) to identify potential pre- and post-operative serum biomarkers in patients with early stage ESCC using metabolomic fingerprint spectrum. Serum samples from preoperative patients with ESCC (ESCC, n = 25), postoperative patients with ESCC (PO, n = 24), and controls (n = 40) were analysed using 1H-NMR spectroscopy. Using orthogonal partial least squares-discriminant analysis, 31 altered serum metabolites were successfully identified among the three groups. These metabolites are indicative of the changes that occur with glycometabolism, the metabolism of fatty acids, amino acids, choline, ketone bodies, nucleotides, and lipids. Based on receiver operating characteristic (ROC) curve analysis and a biomarker panel with an area under the curve (AUC) of 0.969, six serum metabolites (α-glucose, choline, glutamine, glutamate, valine, and dihydrothymine) were selected as potential diagnostic biomarkers for early stage ESCC. Additionally, four potential PO biomarkers (α-glucose, pyruvate, glutamate, and valine) with an AUC of 0.985 were selected to distinguish ESCC and PO. Many metabolites trended towards normalisation in PO patients, with only choline remaining high with an AUC of 0.858, suggesting that it may be a valuable potential biomarker for neoplasm progression, recurrence, chemoradiotherapy, and prognosis. 1H-NMR spectroscopy may be a useful tumour detection approach in the early diagnosis of ESCC. These results also indicate that it is useful to differentiate pre- and post-operative ESCC, evaluate surgery therapeutic responses, and monitor postoperative chemoradiotherapy.

Entities:  

Keywords:  1H-NMR spectroscopy; Esophageal squamous cell carcinoma; biomarker; metabolomics

Year:  2019        PMID: 30899382      PMCID: PMC6413262     

Source DB:  PubMed          Journal:  Am J Transl Res            Impact factor:   4.060


  5 in total

1.  Serum metabolomics analysis for the progression of esophageal squamous cell carcinoma.

Authors:  Xia Li; Lihong Zhao; Mengke Wei; Jiali Lv; Yawen Sun; Xiaotao Shen; Deli Zhao; Fuzhong Xue; Tao Zhang; Jialin Wang
Journal:  J Cancer       Date:  2021-04-02       Impact factor: 4.207

2.  Plasma Metabolomics Reveals Diagnostic Biomarkers and Risk Factors for Esophageal Squamous Cell Carcinoma.

Authors:  Mengjie Yu; Wei Wen; Xin Yi; Wei Zhu; Jiye Aa; Guangji Wang
Journal:  Front Oncol       Date:  2022-02-07       Impact factor: 6.244

3.  Oxidative stress genes in patients with esophageal squamous cell carcinoma: construction of a novel prognostic signature and characterization of tumor microenvironment infiltration.

Authors:  Wei Liu; Hao-Shuai Yang; Shao-Yi Zheng; Hong-He Luo; Yan-Fen Feng; Yi-Yan Lei
Journal:  BMC Bioinformatics       Date:  2022-09-30       Impact factor: 3.307

4.  Plasma Choline as a Diagnostic Biomarker in Slow Coronary Flow.

Authors:  Yuan-Ting Zhu; Ling-Ping Zhu; Zhen-Yu Wang; Xue-Ting Qiu; Wan-Zhou Wu; Wei-Wang Liu; Yu-Yu Feng; Wen-Kai Xiao; Xin Luo; Zhen-Yu Li; Chuan-Chang Li
Journal:  Cardiol Res Pract       Date:  2020-01-25       Impact factor: 1.866

5.  Metabolomic study of soft corals from the Colombian Caribbean: PSYCHE and 1H-NMR comparative analysis.

Authors:  Liliana Santacruz; Diana X Hurtado; Roisin Doohan; Olivier P Thomas; Mónica Puyana; Edisson Tello
Journal:  Sci Rep       Date:  2020-03-25       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.